SO
CLVS

STRS Ohio’s Clovis Oncology, Inc. CLVS Stock Holding History

STRS Ohio’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-2,500
Closed -$132K – 2207
2018
Q1 		$132K Sell
2,500
-600
-19% -$35K ﹤0.01% 1546
2017
Q4 		$210K Sell
3,100
-2,100
-40% -$147K ﹤0.01% 1499
2017
Q3 		$428K Sell
5,200
-400
-7% -$31.7K ﹤0.01% 1394
2017
Q2 		$524K Sell
5,600
-8,479
-60% -$519K ﹤0.01% 1324
2017
Q1 		$896K Buy
+14,079
New +$856K ﹤0.01% 897
2015
Q4 		– Sell
-9,039
Closed -$831K – 1973
2015
Q3 		$831K Sell
9,039
-3,740
-29% -$324K ﹤0.01% 926
2015
Q2 		$1.12M Buy
+12,779
New +$1.09M ﹤0.01% 788
2014
Q2 		– Sell
-14,000
Closed -$970K – 1782
2014
Q1 		$970K Hold
14,000
– – ﹤0.01% 757
2013
Q4 		$844K Buy
14,000
+2,600
+23% +$141K ﹤0.01% 863
2013
Q3 		$693K Sell
11,400
-11,479
-50% -$814K ﹤0.01% 1083
2013
Q2 		$1.53M Buy
+22,879
New +$1.03M 0.01% 641

Other funds holding CLVS

PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

STRS Ohio's CLVS Position: Q2 2018 in Review

STRS Ohio sold out of Clovis Oncology, Inc. (CLVS) in Q2 2018, closing a stake of 2,500 shares — an estimated $132K sold.

STRS Ohio first reported a position in CLVS in Q2 2013 and held it in 11 quarters. The position peaked at $1.53M in Q2 2013. 210 funds tracked by Wall St. Rank hold CLVS as of Q2 2018.

  • STRS Ohio reported no remaining Clovis Oncology, Inc. position as of Q2 2018 after selling out during the quarter.
  • STRS Ohio sold 2,500 Clovis Oncology, Inc. shares in Q2 2018, an estimated $132K.
  • STRS Ohio first reported a position in Clovis Oncology, Inc. in Q2 2013 and held it in 11 quarters.
  • STRS Ohio's Clovis Oncology, Inc. position peaked at $1.53M in Q2 2013.
  • 210 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2018.

Based on STRS Ohio's 13F filing for Q2 2018, filed 6 Aug 2018.